Castle Biosciences CSTL Accretion (Amortization) of Discounts and Premiums, Investments
Accretion (Amortization) of Discounts and Premiums, Investments at other companies
Other financials
Where this comes from
Reported directly by Castle Biosciences in its filing.
Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.
The official record: Castle Biosciences’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Castle Biosciences's accretion (amortization) of discounts and premiums, investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Castle Biosciences's accretion (amortization) of discounts and premiums, investments?
- Castle Biosciences (CSTL) reported accretion (amortization) of discounts and premiums, investments of $454K in Q1 2026.
- How has Castle Biosciences's accretion (amortization) of discounts and premiums, investments changed year-over-year?
- Castle Biosciences's accretion (amortization) of discounts and premiums, investments decreased by 68.4% year-over-year, from $1.44M to $454K.
- What is the long-term trend for Castle Biosciences's accretion (amortization) of discounts and premiums, investments?
- Over 3 years (2022 to 2025), Castle Biosciences's accretion (amortization) of discounts and premiums, investments has grown at a 45.6% compound annual growth rate (CAGR), from $1.37M to $4.22M.
- What does accretion (amortization) of discounts and premiums, investments mean?
- This represents the non-cash adjustment to net income resulting from the amortization of premiums or the accretion of discounts on debt securities held as investments. It reflects the systematic recognition of interest income over the life of the investment to align the carrying value with the par value. Investors use this to reconcile the difference between cash interest received and the interest income reported on the income statement.